Once-weekly vs twice-weekly carfilzomib improves outcome in RRMM
Twice-weekly carfilzomib (Kd) at a dose of 27 mg/m2 is approved for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Dr. María-Victoria Mateos (University Hospital of Salamanca, Spain) presented the first results of the phase III A.R.R.O.W. study, which compared a more convenient regimen of once-weekly Kd (70 mg/m2) to twice-weekly Kd (27 mg/m2) in RRMM patients who received 2-3 lines of prior therapy (n=478). After a median follow-up of approximately one year, median PFS was 11.2 months in the once-weekly arm vs 7.6 months in the twice-weekly arm (HR 0.69, p=0.0014). The ORR was significantly higher as well (63% vs 41%, respectively). The overall safety profile was comparable between both arms.